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Abstract 
Objective: Promoting healthy communities through the provision of accessible quality healthcare services is a common mission shared 
by schools of pharmacy, public health departments, and governmental agencies. The following study seeks to identify and detail the 
benefits of collaboration between these different groups. Methods: In total, 112 mobile clinics targeting Medicare beneficiaries were 
held in 20 cities across Northern/Central California from 2007 to 2016. Under the supervision of licensed pharmacists, trained student 
pharmacists provided vaccinations, health screenings, Medicare Part D plan optimization services, and Medication Therapy 
Management (MTM) to patients at each clinic site. Clinic support was extended by public health departments, governmental agency 
partners, and a health professional program. Results: Since clinic inception, 8,996 patients were provided services. In total, 19,441 
health screenings and 3,643 vaccinations were collectively provided to clinic patients. We assisted 5,549 beneficiaries with their Part D 
benefit, resulting in an estimated aggregate out-of-pocket drug cost savings of $5.7 million. Comprehensive MTM services were 
provided to 4,717 patients during which 8,184 medication-related problems (MRPs) were identified. In 15.3% of patients, the MRP was 
determined severe enough to warrant prescriber follow-up. In total, 42.9% of clinic patients were from racial/ethnic minority groups 
and 25.5% had incomes ≤150% of the Federal Poverty Level. Conclusion: Collaboration between a school of pharmacy, public health 
departments, and governmental organizations can effectively serve Medicare beneficiary populations and result in: 1) lower out-of-
pocket drug costs, 2) minimization of medication-related problems, 3) increased vaccination uptake, and 4) increased utilization of 
health screenings. 
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Background 
Healthy People 2020 provides national objectives for 
improving the health of Americans through a multidimensional 
approach that involves organizational and community 
collaboration, empowers individuals to make informed health 
decisions, and measures the impact of preventative activities.1   
 
Healthy People 2020 consists of key topic areas including 
improving access to health care services, increasing 
immunization rates, optimizing health outcomes for older 
adults, solidifying public health infrastructure, and creating 
environments that reduce the impact of social determinants 
on health. Promoting healthy communities through the 
provision of accessible, high-quality health care is a mission  
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shared by schools of pharmacy, public health departments, 
and governmental agencies.2 Previous research has 
demonstrated tangible benefits of intergroup collaboration 
including expanded vaccination access, point-of-care testing, 
information sharing, and improved care for vulnerable 
populations.2,3 
 
Medicare beneficiaries represent a growing population, many 
of whom incur high annual healthcare expenditures. There are 
currently close to 58 million Medicare beneficiaries, 84% of 
whom are 65 years of age or older.4 In 2012, per capita health 
care expenditures for adults 65 years of age and older were 
approximately three times higher than they were for younger 
patients.5 Prescription drug expenditures are the third largest 
cost driver of healthcare expenditures, with Medicare 
spending an average of $2,203 per beneficiary in 2015 on 
outpatient prescription drugs.6 
 
Medicare Part D is the outpatient prescription drug benefit 
available to beneficiaries. Patel et al. sought to examine the 
potential out-of-pocket (OOP) cost savings a beneficiary could 
realize by optimizing their Part D plan.7 It was found that 89.7% 
of beneficiaries could reduce their OOP cost by switching to a 
different Part D plan for the upcoming year.7  Cutler et al. 
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performed a cross-sectional study including 1,300 
beneficiaries with annual incomes less than 300% of the 
Federal Poverty Level who received Medicare Part D assistance 
at community outreach events and found that OOP costs were, 
on average, reduced by 68% following counseling 
recommendations.8  Findings from these studies demonstrate 
that community outreach targeting Medicare beneficiaries can 
help optimize Part D plan selection and significantly reduce 
OOP prescription drug costs. 
 
Aside from high OOP drug costs, the complexity of medication 
regimens can also negatively affect medication adherence and 
patient outcomes.9 Americans age 65 years and older take a 
median of four prescription medications a month, and 39% 
take five or more.10,11  As such, many Medicare beneficiaries 
face a high drug burden and stand to benefit from Medication 
Therapy Management (MTM) services. During an MTM 
intervention, a pharmacist or qualified healthcare provider 
reviews a patient’s medication regimen, discusses their 
concerns/findings with the patient, and addresses any 
medication-related problems (MRPs). By meeting certain 
eligibility criteria, Medicare beneficiaries can qualify for 
receipt of these services through their Part D plan. In 2014, 
around 8% of beneficiaries or 2.5 million individuals were 
eligible for MTM services through their Part D benefit.12  
Despite the availability of MTM services, drug therapy for 
many beneficiaries may still be suboptimal. The Centers for 
Medicare & Medicaid Services (CMS) found that only 10% of 
participating beneficiaries receive a comprehensive 
medication review, a required component of MTM programs, 
each year.12 
 
The underutilization of MTM services is troubling since MTM 
has been shown to be effective in improving medication 
adherence and reducing adverse drug events in the elderly.13 
A 2010 study conducted by the Department of Health and 
Human Services reported that 42% of adverse events 
experienced by hospitalized Medicare beneficiaries were due 
to medications.14  Moreover, Viswanathan et al. found that 
over 40% of severe drug events were preventable.15  Lindblad 
et al. conducted a study including 1,340 veterans which found 
that 15.3% of them experienced a drug-disease state 
interaction.16  
 
Medication Therapy Management programs can improve 
disease state outcomes by optimizing medication regimens 
and improving adherence. Theising et al. found that receiving 
MTM services led to reduced blood sugar levels in patients 
with diabetes and lower blood pressure in those with 
hypertension.17  Perloth et al. found that beneficiaries with 
congestive heart failure, chronic obstructive pulmonary 
disease (COPD), and/or diabetes who received MTM services 
had 11%-40% higher medication adherence rates compared to 
those who did not receive MTM services.18 These studies 
highlight the potential value of MTM interventions. 
Immunizations and preventative health screenings for chronic 
conditions such as diabetes, hypertension, and osteoporosis 
can also be beneficial in maintaining the health and well-being 
of Medicare beneficiaries. Influenza and pneumonia represent 
the eighth-leading cause of death among adults age 65 years 
and older in the United States, accounting for 44,836 deaths of 
the elderly in 2014.19 Although influenza and pneumonia are 
largely preventable, vaccination rates remain subpar. In 2015, 
the Centers for Disease Control and Prevention (CDC) reported 
that 63.4% of adults age 65 years and older received a flu 
vaccine in the previous year, and 63.6% had received a 
pneumococcal vaccine in their lifetime.20  
 
Immunization uptake has plateaued over the last decade and 
remains far short of the 90% coverage goal for each vaccine set 
by Healthy People 2020.21-23  Recommendations were made in 
2014 for adults age 65 years and older to receive both 
pneumococcal vaccines, however uptake has been slow with 
only 18.3% of adults receiving both vaccines two years after 
the recommendation.23  Local public health departments have 
attempted to increase flu vaccine uptake in underserved 
populations through partnerships with community-based 
organizations and hosting vaccine outreach clinics. High 
patient satisfaction and increased vaccination uptake show 
that such collaborations can be  fruitful.24 
 
Existing collaborations between pharmacy and public health 
have proven beneficial in helping address unmet public health 
needs. During the H1N1 pandemic in 2009-2010, a 
collaboration between pharmacies and a local health 
department in Palm Beach County, Florida helped distribute 
vaccines and educate patients. This collaboration resulted in 
the distribution of 200,000 flu information cards to 250 
community pharmacies and in-store health clinics by local 
public health departments. Of those surveyed, 90% of 
pharmacy managers reported being asked about influenza by 
their customers, and 64% of pharmacy managers reported 
finding the local health department a useful resource.25  The 
growth of pharmacy and public health collaborations in recent 
years has sparked interest in policy changes to ensure that 
pharmacy-based public health services can be effective and 
sustainable. 
 
Other collaborative programs have been developed with the 
intent of addressing the health care needs of underserved 
populations. The Health Disparities Collaborative and the 
Healthy Communities Access Program were initiated in 
response to the growing disparity of health care access for 
different populations.26 In addition to local health department 
collaborations, partnerships between public health and 
schools of pharmacy have been created to offer students 
patient education opportunities. “AdvoCaring,” a program 
established at Notre Dame of Maryland University’s Pharmacy 
School, provides free health services such as blood pressure 
monitoring and educational sessions on select health topics to 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                          2018, Vol. 9, No. 1, Article 2                            INNOVATIONS in pharmacy   3 
 
populations in need through partnerships with local 
agencies.27 
 
Medicare beneficiaries stand to benefit from collaborations 
between schools of pharmacy, public health departments, and 
governmental agencies.  In this paper, we describe a 
collaborative approach between a School of Pharmacy, 
multiple public health departments, and different 
governmental agencies to assist Medicare beneficiaries in 
lowering their OOP drug costs, ensuring safe and effective use 
of their medications through provision of MTM services, and 
improving access to vaccinations and preventive health 
screenings. 
  
Methods 
In total, 112 mobile health clinics targeting Medicare 
beneficiaries (Mobile Medicare Clinics) were conducted by the 
University of the Pacific Thomas J. Long School of Pharmacy 
and Health Sciences during the annual fall Medicare open 
enrollment window between 2007 and 2016. All clinics 
occurred at locations throughout northern and central 
California. The clinics began by offering only Medicare Part D 
plan optimization services and expanded over the years to 
include MTM, vaccinations, and a myriad of free health 
screenings. All screenings and services were provided by 
trained pharmacy students under the supervision of licensed 
pharmacists. 
 
Medicare Part D plan optimization included evaluating a 
beneficiary’s Part D drug plan and identifying if a lower cost 
plan was available by inputting beneficiary specific information 
(e.g., medication regimen, preferred pharmacy) into the online 
Medicare Plan Finder Tool (available at www.medicare.gov). 
Potential OOP cost savings opportunities, by switching Part D 
plans, were recorded for each assisted beneficiary.  
 
In 2010, the Mobile Medicare Clinics expanded to include 
MTM services. The provision of MTM services for assisted 
beneficiaries included a systematic 12-point process during 
which the following MRPs were evaluated: 1) expired/out-of-
date medication(s), 2) untreated condition(s), 3) therapeutic 
duplication(s), 4) medication(s) without indication, 5) 
contraindication(s), 6) potentially inappropriate medication(s) 
for older adults, 7) drug-drug interaction(s), 8) drug-
disease/condition interaction(s), 9) awareness of the purpose 
of each medication, 10) how patient reported taking each 
medication as compared to labeled directions, 11) adverse 
drug reaction(s), and 12) the availability of cheaper 
therapeutic alternative(s). Drug information databases 
including Lexicomp®, Clinical Pharmacology®, UpToDate®, Facts 
and Comparisons®, and Micromedex® were consulted to help 
facilitate each MTM intervention. The type and frequency of 
each MRP was recorded during each MTM intervention. 
Student findings were presented to a supervising licensed 
pharmacist during each intervention and a determination was 
made as to the severity of each identified MRP. With patient 
consent, prescribers were notified of all severe MRPs. 
Demographic data (e.g., race/ethnicity, income, etc.) were 
collected from each assisted beneficiary during the Part D 
and/or MTM intervention via a standardized data collection 
tool that was approved by the University’s Institutional Review 
Board. 
 
In addition to Part D and MTM services, the clinics expanded 
to provide vaccinations (first introduced in 2010) and health 
screenings (first introduced in 2011). Immunizations including 
influenza, pneumococcal (both PCV13 and PPSV23), zoster, 
and Tdap vaccines have been available at clinic sites. Diabetes 
and cholesterol screening, blood pressure testing, bone 
mineral density testing, falls risk assessment, anemia testing, 
memory decline screening, depression screening, 
asthma/COPD screening, insomnia screening, and anxiety 
testing have also been made available at clinic sites. 
 
Our Mobile Medicare Clinics sought collaborative 
opportunities with strategic partner groups over the years. 
Partnerships were forged with the following governmental 
agencies: Health Insurance Counseling & Advocacy Program 
(HICAP), County Public Health Departments, CMS, Social 
Security Administration (SSA), and California Department of 
Aging (CDA). In addition, partnerships with Clinic host sites and 
other professional programs [University of San Francisco (USF) 
Nurse Practitioner Program] have also been cultivated. The 
nature of these partnerships and the support provided by each 
partner group can be found in Table 1. 
 
Results 
In aggregate, 8,996 patients were assisted at Clinic sites 
between 2007 and 2016. In total, 42.9% of patients self-
identified as belonging to a racial and/or ethnic minority 
group, and 25.5% had incomes less than or equal to 150% of 
the Federal Poverty Level. 
 
Part D optimization services were provided to 5,549 
beneficiaries since the inception of the Clinics. It was observed 
that 76.3% of assisted beneficiaries had the potential to lower 
their OOP costs by switching Part D drug plans in the upcoming 
year (Table 2). In aggregate, beneficiaries could realize $5.7 
million (or $1,031/beneficiary per annum) by switching Part D 
plans during the annual Medicare Part D open enrollment 
period. Mean potential OOP savings through Part D plan 
optimization services increased with time, growing at an 
average rate of 11.1% per year. In addition, there was a 154% 
increase in the number of Medicare beneficiaries assisted with 
Part D plan optimization services since the partnership with 
CMS first began. 
 
In total 4,717 patients were provided MTM services at Clinic 
sites between 2010 and 2016. A total of 8,184 MRPs were 
identified, or roughly 1.74 MRPs/MTM intervention (Table 3). 
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Approximately 15.3% of patients who were provided with 
MTM services had a severe MRP that warranted prescriber 
contact and follow-up. A noticeable increase in MRPs 
identified per patient was observed since the interprofessional 
collaboration with USF’s nurse practitioner program began in 
2015. 
 
In total, 3,643 vaccines (72.9% of which were for the flu 
vaccine) were administered to Clinic patients. The number of 
vaccines provided to Clinic patients increased between 106% 
and 225% each year since the partnership with County Public 
Health was first forged. The number of health screenings (e.g., 
blood glucose, blood pressure, and cholesterol testing) totaled 
19,441 at Clinic sites between 2011 and 2016 (Table 4). As 
such, on average 3,240 free health screenings were provided 
to the community each year and the average patient took 
advantage of 2.5 such screenings during their attendance at a 
Clinic site. 
 
Discussion 
There was a 1,815% increase in the number of Clinic patient 
attendees from 2007 to 2016. The exponential growth in those 
served is most likely attributable to the support, and 
collaborative nature, of our external partners. 
 
With regard to Part D plan optimization, the number of 
beneficiaries assisted grew every year since the CMS 
partnership began in 2011 (Table 1). The most likely reason for 
the observed growth is that CMS’s onsite/phone support 
during Clinics enabled more efficient beneficiary eligibility 
verification. This significantly reduced the average length of 
time per intervention and allowed for a greater number of 
beneficiaries to receive Part D services at each Clinic site. The 
fact that a smaller (72.8% vs. 95.2%) percentage of patients 
were observed to have potential OOP cost-savings by 
switching Part D plans in 2016 versus 2007 is likely attributable 
to the number of plan offerings. In 2007, there were 55 stand-
alone Part D prescription drug plans available in California. In 
contrast, there were only 24 such plans in 2017.28 The decrease 
in plan offerings means that beneficiaries now have fewer 
plans from which to choose that could result in lower OOP cost 
savings. 
 
The number of patients receiving MTM services consistently 
increased every year the service was offered (Table 3). There 
was a notable increase in the average number of MRPs 
identified per MTM intervention starting 2014 and continuing 
through 2016. We posit that this uptick occurred because of 
the interprofessional collaboration with the USF Nurse 
Practitioner program. Starting in 2014, nurse practitioner 
students assisted pharmacy students in providing the MTM 
intervention and helped collect medical and medication 
information from the patient while drawing on their own 
expertise and training focus. This comprehensive approach 
was much more thorough than that which would be possible 
by any one type of health care professional student alone. 
Despite the increase in the number of MRPs identified, the 
percentage of severe MRPs remained constant during this 
time. This suggests that the collaboration mostly helped 
identifying problems that were less severe in nature and/or 
that once identified and addressed it was unlikely that those 
same severe MRPs would be found when patients returned the 
following year. 
 
The number of vaccines administered in a given year increased 
from 208 to 677 following collaboration with Public Health 
(Table 4). In a typical year, between 150 and 250 doses of the 
flu vaccine were secured from County Public Health 
departments. This flu vaccine supply enabled us to provide the 
influenza vaccine to Clinic patients regardless of their 
insurance coverage or ability to pay. The number of 
administered pneumococcal vaccinations increased by 44% 
from 2013 to 2015 and made up about 30% of provided 
vaccinations in 2015. The pneumococcal vaccine uptake 
increased and plateaued with a peak in 2015 which is likely 
attributable to the 2014 CDC recommendations to provide 
adults age 65 years and older with one dose of each vaccine 
(13-valent pneumococcal conjugate vaccine [PCV13] and the 
23-valent pneumococcal polysaccharide vaccine [PPSV23]) six 
to twelve months apart.29 While there has been an overall 
increase in vaccines administered since 2010, a steady decline 
from 2013 has been observed. A plausible reason for this 
finding is that once patients have received the shingles, Tdap 
and both pneumococcal vaccines they have been brought up-
to-date and thus only need an annual flu vaccine. Vaccine 
delivery and uptake are multifactorial and requires much more 
logistical, financial and faculty support to ensure its growth 
and sustainability compared to lower cost health screenings or 
cognitive services (e.g., MTM). 
 
Partnership between a school of pharmacy, governmental 
health organizations, community partners and other health 
professional programs can effectively provide much-needed 
health care screenings/services to underserved and 
underrepresented communities. In doing so, collaborations of 
this type have the potential to reduce OOP health care costs, 
promote medication safety, improve access to preventative 
health screenings, and aid communities in achieving public 
health goals. Viewing this collaborative model in the frame of 
pharmacy education can transform the way students perceive 
current healthcare challenges and integrate their skills to 
effectuate change.  Raising student awareness of public health 
is key to improving healthcare access to underserved 
communities. By partnering with public health, pharmacy 
students have the opportunity to participate in public health 
initiatives and provide services that can benefit targeted 
communities.30 
 
In November 2015, recognizing the increasing synergy 
between public health and pharmacy, the American Public 
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Health Association’s Governing Council approved the 
development of a Pharmacy Public Health Special Primary 
Interest Group (SPIG). This group focused on advancing the 
pharmacist’s role in promoting public health, encouraging safe 
medication use, and improving patient outcomes. Due to an 
aging population and rising healthcare costs, pharmacists and 
by extension, pharmacy students are well positioned to have a 
meaningful role impacting patient care. Offering services such 
as Part D optimization, MTM, vaccinations and health 
screenings can help reduce patient and the healthcare system 
costs, increase medication adherence, and improve health 
outcomes. 
 
One limitation of this study is the exploratory nature of the 
outcomes measured, such as potential savings and MRPs 
identified as opposed to realized savings or hospitalizations 
avoided. Due to the nature of the mobile health clinics, there 
was no quantitative way to measure the impact of each 
individual organization. Further research is needed to 
determine the impact of services provided on the public health 
sector as well as clinical and economic benefits.   
 
Conclusion 
This study described the nature of support and resultant 
outcomes from a collaborative approach between a school of 
pharmacy, public health, and governmental organizations to 
improve the economic and clinical outcomes of community-
dwelling Medicare beneficiaries. We found that the number of 
patients served increased greatly through this collaborative 
approach and benefits to Clinic attendees included lower OOP 
drug costs, identification and minimization of medication-
related problems, increased vaccine uptake and increased 
utilization of preventative healthcare screenings.  
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Table 1. Clinic Partners and the Nature of their Provided Support Either Prior to and/or During Each Mobile Medicate Clinic 
 
Partners 
(first year of 
partnership) 
 
Prior to Clinic 
 
At Clinic 
Health Insurance 
Counseling & 
Advocacy Program 
(2007) 
• Assisted in disseminating Clinic flyers 
throughout the community 
• Helped establish new Clinic host sites 
• Provided in-person Clinic support to answer 
beneficiary  questions about Medicare 
Advantage plan offerings in their county, 
Medigap policies, and Medicare’s general 
benefit structure 
County Public Health 
Services (2010) 
• Hosted focus groups to test the effectiveness 
of Clinic marketing material 
• Funded event(s) flyer production and 
distribution to increase awareness of Clinics 
• Advertised Clinics throughout the community 
• Funded a sensitivity training program for 
pharmacy students 
• Supplied influenza vaccines for county 
residents 
Centers for Medicare 
& Medicaid Services 
(2011) 
• Assisted in disseminating Clinic flyers 
throughout the community 
• Provided direct support during each Clinic to 
assist in beneficiary eligibility verification and 
technical questions 
Social Security 
Administration 
(2012)  
• Provided onsite Clinic support for 
beneficiaries needing help in applying for the 
Low-Income Subsidy (LIS) 
California 
Department of Aging 
(2012) 
• Assisted in disseminating Clinic flyers 
throughout the community 
• Provided grant funding to help subsidize the 
cost of Clinic offerings 
• Provided onsite Clinic support  to share 
resources available to beneficiaries 
University of San 
Francisco (USF) 
Nurse Practitioner 
Program (2014) 
• Participated in simulation exercises to 
prepare students (pharmacy and nurse 
practitioners) for interprofessional 
collaborative patient care at Clinic sites 
• Provided interprofessional collaboration 
during Clinic MTM interventions 
Individual Clinic Host 
Sites 
• Coordinated Clinic patient appointments 
• Provided assistance with Clinic advertisement 
• Educated students on effective 
communication and cultural awareness of the 
target population 
• Provided venue space 
• Provided logistical support 
• Provided food for volunteers 
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Table 2. Resultant Outcomes from Medicare Part D Plan Optimization Services from 2007-2016 
 
Year 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Number of 
Clinics 6 8 11 9 13 12 14 13 13 13 
Number of 
patients 
assisted with 
Part D 72 315 286 395 540 621 676 754 888 1,002 
Patients with 
potential OOP 
cost savings 
by switching 
Part D plans 
(%) 
 
95.2 
 
85.8 
 
77.8 
 
75.2 
 
81.2 
 
80.2 
 
77.7 
 
69.4 
 
74.5 
 
72.8 
Total 
potential OOP 
savings by 
switching Part 
D plans ($) 
 
35,696 
 
146,627 
 
140,276 
 
174,688 
 
368,660 
 
713,502 
 
660,315 
 
1,043,429 
 
1,320,073 
 
1,121,370 
Avg. annual 
potential OOP 
savings per 
patient ($) 
 
496 
 
646 
 
754 
 
562 
 
814 
 
1,149 
 
972 
 
1,628 
 
 
1,487 
 
1,282 
OOP=out-of-pocket 
Avg.=average 
 
 
 
 
 
Table 3. Medication Therapy Management (MTM) Services and Identified  
Medication Related Problems (MRP’s) from 2007 to 2016 
 
Year 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
 
Number of MTM services 
provided - - - 339 543 583 659 731 865 997 
Total MRPs identified 
Avg. MRP per patient - - - 
 
501 
1.5 
 
431 
0.8 
 
998 
1.7 
 
775 
1.2 
 
1,139 
1.6 
 
1,992 
2.3 
 
2,348 
2.4 
 
Total severe MRPs 
identified 
(%) of MRPs identified 
severe - - - 
 
78 
15.6 
 
103 
23.9 
 
62 
6.2 
 
137 
17.7 
 
79 
6.9 
 
102 
5.1 
 
162 
6.9 
MRP=medication related problems 
MTM=medication therapy management 
Avg.=average 
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Table 4. Vaccine Administration and Aggregate Health Screenings Provided at Clinic Sites from 2007 to 2016 
                                              
Year 
 
Tdap=tetanus, diphtheria, and pertussis vaccine 
Avg.=average 
 
 
 
 
 
 
 
 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
Total clinic patients 72 315 286 401 1,013 1,547 1,279 1,369 1,335 1,379 
Total vaccines administered - - - 208 429 563 677 629 612 525 
Flu 
Number administered                       
(%) of total vaccines - - - 
 
208 
100 
 
294 
68.5 
441 
78.3 
491 
72.5 
436 
69.3 
397 
64.9 
387 
73.7 
Pneumococcal 
Number administered 
(%) of total vaccines - - - - 
59 
13.8 
74 
13.1 
125 
18.5 
138 
21.9 
180 
29.4 
122 
23.2 
Tdap or Zoster 
Number administered 
(%) of total vaccines - - - - 
 
76 
17.7 
48 
8.5 
61 
9.0 
55 
8.7 
35 
5.7 
16 
3.0 
Health screenings 
Number provided 
Avg. screenings per patient 
 
 
- - - - 
 
2,270 
2.2 
2,886 
1.9 
3,223 
2.5 
3,775 
2.8 
3,685 
2.8 
3,602 
2.6 
